Skip to main content

Advertisement

SpringerLink
Log in

Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

To evaluate the situation and perspectives of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected patients, we investigated changes in the incidence, causes, and long-term outcome of this disease in 72 acquired immunodeficiency syndrome (AIDS) patients who were diagnosed with PML from 1996 to 2011. Patients were classified according to the date of diagnosis in the first (1996–2000, n = 35), second (2001–2006, n = 26), and recent or third highly active antiretroviral therapy (HAART) period (2007–2011, n = 11). Overall, the incidence of PML decreased from 14.8 cases/1,000 patients/year in 1996 to 2.6 in 2005 and 0.8 in 2011, and nearly two-thirds of recent cases (64 %) were observed in HIV patients not attending clinical visits. The baseline median CD4+ count was higher in recently PML-diagnosed patients (77 vs. 86 vs. 101 cells/mm3; p < 0.01), and this fact was associated with a cerebrospinal fluid (CSF) inflammatory profile (from 11 to 31 to 55 %, p = 0.007) and with a significantly longer survival (attributable death, 54 vs. 35 vs. 36 %, respectively, p < 0.01). Thus, the overall 1-year and 3-year survival rates were 55 and 50 %, respectively, increasing to 79 % at 1 year for patients with CD4+ count above 100 cells/mm3 at diagnosis. In a Cox regression analysis, an older age (hazard ratio, HR 0.76), a baseline CD4+ count above 100 cells/mm3 (HR 0.33), and a CSF inflammatory profile (HR 0.12) were significantly associated with a longer survival. The clinical presentation and outcome of PML in AIDS patients continue to change dramatically. Now, a declining incidence and long-term survival is observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Richardson EP Jr (1961) Progressive multifocal leukoencephalopathy. N Eng J Med 265:815–823

    Article  Google Scholar 

  2. Gillespie SM, Chang Y, Lemp G et al (1991) Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981–1989. Ann Neurol 30:597–604

    Article  CAS  PubMed  Google Scholar 

  3. Berger JR, Kaszovitz B, Post MJ, Dickinson G (1987) Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 107:78–87

    Article  CAS  PubMed  Google Scholar 

  4. Wyen C, Hoffmann C, Schmeisser N et al (2004) Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 37:1263–1268

    Article  CAS  PubMed  Google Scholar 

  5. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. De Luca A, Giancola ML, Ammassari A et al (2000) The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182:1077–1083

    Article  PubMed  Google Scholar 

  7. Clifford DB, Yiannoutsos C, Glicksman M et al (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52:623–625

    Article  CAS  PubMed  Google Scholar 

  8. Taoufik Y, Gasnault J, Karaterki A et al (1998) Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178:1816–1820

    Article  CAS  PubMed  Google Scholar 

  9. Bossolasco S, Calori G, Moretti F et al (2005) Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 40:738–744

    Article  CAS  PubMed  Google Scholar 

  10. Engsig FN, Hansen AB, Omland LH et al (2009) Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 199:77–83

    Article  PubMed  Google Scholar 

  11. Berenguer J, Miralles P, Arrizabalaga J et al (2003) Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 36:1047–1052

    Article  CAS  PubMed  Google Scholar 

  12. Grabar S, Lanoy E, Allavena C et al (2008) Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 9:246–256

    Article  CAS  PubMed  Google Scholar 

  13. Cinque P, Koralnik IJ, Clifford DB (2003) The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 9(Suppl 1):88–92

    CAS  PubMed  Google Scholar 

  14. Rockstroh JK, Gatell J, Landman R, Antinori A (2010) Management of late-presenting patients with HIV infection. Antivir Ther 15(Suppl 1):25–30

    Article  PubMed  Google Scholar 

  15. Fedele CG, Ciardi M, Delia S, Echevarria JM, Tenorio A (1999) Multiplex polymerase chain reaction for the simultaneous detection and typing of polyomavirus JC, BK and SV40 DNA in clinical samples. J Virol Method 82:137–144

    Article  CAS  Google Scholar 

  16. Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45–55

    PubMed  Google Scholar 

  17. Cinque P, Bossolasco S, Brambilla AM et al (2003) The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 9(Suppl 1):73–80

    CAS  PubMed  Google Scholar 

  18. Couzigou C, Semaille C, Le Strat Y et al (2007) Differential improvement in survival among patients with AIDS after the introduction of HAART. AIDS Care 19:523–531

    Article  CAS  PubMed  Google Scholar 

  19. Khanna N, Elzi L, Mueller NJ et al (2009) Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 48:1459–1466

    Article  PubMed  Google Scholar 

  20. Colubi MM, Pérez-Elías MJ, Elías L et al (2012) Missing scheduled visits in the outpatient clinic as a marker of short-term admissions and death. HIV Clin Trials 13:289–295

    Article  PubMed  Google Scholar 

  21. Falcó V, Olmo M, del Saz SV et al (2008) Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49:26–31

    Article  PubMed  Google Scholar 

  22. Giudici B, Vaz B, Bossolasco S et al (2000) Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30:95–99

    Article  CAS  PubMed  Google Scholar 

  23. Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998) Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44:341–349

    Article  CAS  PubMed  Google Scholar 

  24. Cinque P, Pierotti C, Viganò MG et al (2001) The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 7:358–363

    Article  CAS  PubMed  Google Scholar 

  25. Gasnault J, Kahraman M, de Goër de Herve MG, Durali D, Delfraissy JF, Taoufik Y (2003) Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17:1443–1449

    Article  PubMed  Google Scholar 

  26. Marzocchetti A, Sanguinetti M, Giambenedetto SD et al (2007) Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. J Neurovirol 13:338–346

    Article  CAS  PubMed  Google Scholar 

  27. Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ (2005) Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19:2069–2076

    Article  PubMed  Google Scholar 

  28. Drake AK, Loy CT, Brew BJ et al (2007) Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol 14:418–423

    Article  CAS  PubMed  Google Scholar 

  29. Lanoy E, Guiguet M, Bentata M et al (2011) Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 76:644–651

    Article  CAS  PubMed  Google Scholar 

  30. Gasnault J, Lanoy E, Bentata M, Gulgust M, Costagliola D (2008) Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). In: Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, USA, February 2008

  31. Tada H, Rappaport J, Lashgari M, Amini S, Wong-Staal F, Khalili K (1990) Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci USA 87:3479–3483

    Article  CAS  PubMed  Google Scholar 

  32. Berger JR, Chauhan A, Galey D, Nath A (2001) Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 7:329–338

    Article  CAS  PubMed  Google Scholar 

  33. Gasnault J, Costagliola D, Hendel-Chavez H et al (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Khanna N, Wolbers M, Mueller NJ et al (2009) JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 83:4404–4411

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A (1997) Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 11:1–17

    Article  CAS  PubMed  Google Scholar 

  36. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A (2005) Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43:4175–4177

    Article  PubMed Central  PubMed  Google Scholar 

  37. Cinque P, Vago L, Dahl H et al (1996) Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10:951–958

    Article  CAS  PubMed  Google Scholar 

  38. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999) JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52:253–260

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

No author has a commercial or other association that may pose a conflict of interest. All research was conducted within the guidelines of ethical principles and local legislation.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Ramón y Cajal Hospital, 28034, Madrid, Spain

    J. L. Casado, J. García, E. Navas, A. Moreno & S. Moreno

  2. Department of Neurology, Ramón y Cajal Hospital, Madrid, Spain

    I. Corral

  3. Department of Radiology, Ramón y Cajal Hospital, Madrid, Spain

    J. Martinez-San Millán

Authors
  1. J. L. Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Martinez-San Millán
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Navas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. L. Casado.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casado, J.L., Corral, I., García, J. et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33, 179–187 (2014). https://doi.org/10.1007/s10096-013-1941-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-013-1941-6

Keywords

Search

Navigation